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Abstract Psychological factors may influence survival
in breast cancer patients but results of previous research are
inconclusive. This prospective population-based study
tested whether depression predicts mortality in breast
cancer patients. Routinely collected depression screening
data were merged with electronically archived provincial
cancer registry data and censored data from British
Columbia Vital Statistics (extracted in December 2012).
Cox proportional-hazards regression analyses were con-
ducted to predict all-cause and breast cancer-specific
mortality as a function of depression after controlling for
biomedical confounders. Of 1,646 patients, 1,604 had
breast cancer stages I–III and 42 had stage IV breast can-
cer. 176 (11.0 %) versus 28 (66.7 %) were deceased after a
median follow-up of 76 months. In patients with curable
breast cancer, depression predicted all-cause (HR = 1.54
(95 % CI 1.06–2.25); p = 0.024), but not breast cancer-
specific mortality (HR = 1.51 (95 % CI 0.95–2.41);
p = 0.084). No association was shown for metastatic dis-
ease. Stage-specific analyses demonstrated a 2–2.5-fold
increase in breast cancer-specific and all-cause mortality in
patients with stage I and II disease, but not in patients with
stage III or IV breast cancer. In stage I breast cancer
patients, age moderated effects of depression such that
depressed younger patients diagnosed at age 45 (i.e., mean
age -1SD) showed a ninefold (HR = 9.82 (95 % CI
2.26–42.68); p = 0.002) increase in all-cause mortality and
depressed patients at 57 a 3.7-fold (HR = 3.69 (95 % CI
1.44–9.48); p = 0.007) increase, while no association was
evident in older patients at age 69 (mean age ?1SD).
Depression is strongly associated with mortality in younger
patients with early stage breast cancer.
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Introduction
The question of whether psychological factors increase the
likelihood of developing cancer and can influence the
course of the disease has been of interest for the past three
decades [1]. Meta-analytic data demonstrates that depres-
sion is a chronic problem in cancer patients and differen-
tiates them from the general population [2]. Because cancer
patients are more likely to present with ongoing depressive
symptoms, depression may have a greater propensity to
predict their mortality [3]. Recent meta-analyses of pro-
spective research with mixed types of cancers indicate that
depression at the time of diagnosis is associated with an
increase in mortality [4, 5]. However, the majority of past
findings are difficult to compare because of a lack of
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control for biomedical prognosticators, use of mixed
patient samples with various tumor types, and differences
in the time point of depression assessment. Therefore, the
present study tests associations of depression at the time of
diagnosis with mortality in a large population-based sam-
ple of women with breast cancer.
Although the question of whether or not psychological
factors predict mortality in women with breast cancer
has been widely studied, findings are not consistent.
Most studies based on patient self-report of depression
using questionnaires failed to identify a relationship
between depression and survival [6–11], whereas two
studies demonstrated prospective associations of depres-
sion with survival [12, 13]. Interestingly, studies that
used depression scales validated for patients with cancer
[14] such as the Hospital Anxiety and Depression Scale
[15] or the Center for Epidemiological Studies Depres-
sion Scale [16] were more likely to identify a relation-
ship of depression and mortality [12, 13]. Based on
clinician diagnoses, large retrospective epidemiological
studies also reported a significant relationship between
depression and survival in breast cancer patients, such
that depression was associated with a 1.3–1.4-fold
decrease in survival [17, 18].
Furthermore, the time point of depression assessment
also may contribute to random error in findings. Most
cross-sectional studies where depression was measured at
various time points after diagnosis failed to identify an
association [10, 11], likely due to differences in where
patients were in the cancer care trajectory, which likely
influences concomitant mood symptoms. As well, the
recency of follow-up merits attention in interpreting
inconclusive findings among studies. A study that investi-
gated depression as a predictor of mortality at longer fol-
low-ups, that is, 5 and 10 years after diagnosis,
demonstrated a significant association at 5 years, but not at
10 years, after diagnosis [9, 12]. The decrease in strength
of an association over several years may be rooted in the
sensitivity to change of depression ratings, such that a
single rating loses predictive validity over time. Finally,
high survival rates of breast cancer and a minority of
patients presenting clinical symptoms of depression create
problems for more recent studies in attaining high statis-
tical power and reliability.
Interestingly, the interaction of depression with age in
predicting survival has rarely been studied, despite evi-
dence that the risk of local recurrences, distant metastases
and survival depend on the patients’ age at diagnosis [19–
21]. Since prognoses for younger women tend to be worse
[19–21], the disease is more likely perceived as threatening
and therefore potentially more likely to result in depression
and to be accompanied by a stronger biologic stress
response in these women.
Additional factors likely play a role in breast cancer
survivorship of younger women, since differences in breast
cancer survival rates are only in part due to a greater
likelihood of younger women being diagnosed with a more
aggressive cancer that is usually at a later stage [21]. For
example, the diagnosis of breast cancer may not have as
severe an impact on the functional status or life expectancy
of older as compared to younger women [19–21]. Coupled
with the fact that depression often diminishes with age
[22], this suggests that a diagnosis of breast cancer might
be less likely to activate a stress response in older women.
In contrast, a cancer diagnosis represents a drastic change
in life expectancy [19–21] and quality of life for younger
women and may be their first serious illness. Breast cancer
treatments differ according to patients’ age as well. On
average, younger women with breast cancer are more likely
to be treated with chemotherapy as well as with more
radical hormonal treatment such as GnRH analogs. These
create more severe side effects than a tamoxifen or aro-
matase inhibitor-only therapy, which are routinely pre-
scribed to postmenopausal women with breast cancer.
These side effects are likely accompanied by greater psy-
chological consequences and poor adherence, which may
further contribute to increased mortality. As a consequence
of these myriad factors, depression may have greater pre-
dictive utility for mortality in younger cancer patients [23].
The present study
The purpose of this prospective cohort study was to test
associations between depression (assessed after diagnosis
but before treatment initiation) with breast cancer-specific
and overall survival in women with newly diagnosed breast
cancer. This design ensures that the psychological assess-
ment is not confounded with emotional changes arising
from the treatment itself; instead it mirrors the patients’
personal resources at the time of cancer diagnosis, repre-
sents a marker of pre-morbid psychological functioning
and reflects individual differences in stress response. We
hypothesized that (1) depression predicts breast cancer-
specific and all-cause mortality; (2) age moderates the
relationship between depression and mortality, with a
younger age and the presence of symptoms of depression
being associated with the greatest risk of mortality.
Methods
Procedures
Within a routine screening program for emotional distress
instituted in 2004, study participants were recruited con-
secutively at two urban cancer centers between 2004 and
374 Breast Cancer Res Treat (2014) 143:373–384
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2009. Patients were routinely assessed for emotional dis-
tress after cancer diagnosis but before treatment initiation
on their first day in the cancer clinic’s hospital, before they
were given detailed prognostic information and a treatment
plan. The recruitment process is described in more detail
elsewhere [23, 24]. These psychosocial data were merged
with electronically archived demographic and biomedical
data, as well as censored data extracted in December 2012
regarding the patients’ survival status. This study received
ethics approval from the local ethics board.
Patients and eligibility
A total of 2,441 patients with breast cancer were initially
entered in the study. Eleven men with breast cancer were
excluded, because male breast cancer is a very unique
condition and difficult to compare with female breast cancer.
Another 564 patients were excluded from the analysis
because they had noninvasive breast cancer (carcinoma
in situ) resulting in 1,866 eligible patients with invasive
female breast cancer stages I–IV. Because of incomplete
data in the Psychosocial Screen for Cancer, another 220
individuals were excluded from analyses resulting in a final
sample of 1,646. Responders (M = 56.19, SD = 12.54) and
non-responders (M = 58.80, SD = 13.38) differed in age
(t (268.38) = 2.72, p = 0.007), such that the patients
included were 2.6 years younger on average. Responders
and non-responders did not differ with respect to their living
situation (i.e., living alone versus not living alone), which
can be considered a proxy for marital status. Nor were there
any differences between responders and non-responders in
terms of biomedical and treatment variables (all p’s [ 0.05).
Median follow-up was 76 months.
Measures
The 21-item Psychosocial Screen for Cancer (PSSCAN)
[27, 28] assesses anxiety and depression symptoms based
on DSM-IV-TR criteria [29], perceived social support,
desired social support, and quality of life. The scale was
specifically developed for use with cancer patients. The
questionnaire’s reliability and validity, including empiri-
cally derived cut-offs and norms, have been reported [25,
26] and meet a high standard of psychometric quality [14].
Only the depression subscale was of interest in the context
of the present study, and anxiety, social support, and
quality of life at diagnosis were not examined.
Depression
Subscale scores can range from 5 to 25, with higher scores
indicating more severe levels of depression, and with cut-
offs of 8 and 11 signifying subclinical and clinical thresholds
of depression, respectively. In comparison with the Hospital
Anxiety and Depression Scale [15], sensitivity and speci-
ficity for the detection of a clinical level of depression were
98 % for sensitivity and 86 % for specificity, respectively.
Two-month test–retest-reliability was r = 0.61 [25].
Previous validation research found that both cancer
outpatients (d = 0.26, p \ 0.001) as well as cancer inpa-
tients (d = 0.70, p \ 0.001) reported significantly higher
levels of depression compared to a community sample [25].
Age was negatively associated with depression in patients
with cancer (q = -0.157, p \ 0.001) as well as in a
healthy community sample (q = -0.190, p \ 0.001)
(unpublished data derived from the validation samples).
The PSSCAN questionnaire was validated in a mixed
sample of cancer outpatients and inpatients, which included
breast cancer patients.
Statistical analyses
Survival data were obtained from the Provincial Vital
Statistics Agency, which provides complete death lists for
all deceased British Columbians on a monthly basis. The
censor date, which is the most recent date that death
information was known, contains complete information on
all patients in the registry, and all cases are censored at that
same date. Censored cases were defined by non-receipt of
information about a patient’s death and death date at the
time of retrieval of survival data. Thus, patients on whom
data on survival status had been missing were categorized
as censored. In this process the censoring mechanism is not
related to the outcome and the assumption of non-infor-
mative as well as right censoring is satisfied.
Survival time was calculated by subtracting the date of
death or censoring from the date of diagnosis. Analyses
were conducted for death resulting from any cause (i.e., all-
cause mortality) and death resulting from breast cancer
(i.e., breast cancer-specific mortality).
Cox proportional-hazards regression analysis uses the
likelihood-ratio statistic and calculates the overall Chi-square.
Parameter estimates for each variable in the model represent
hazard ratios. Cox proportional-hazards regression analyses
were conducted controlling for age, stage, grade, histology,
estrogen receptor, her2-neu status, and treatment variables
(i.e., surgery, radiation, chemotherapy, hormonal therapy).
Given the fact that estrogen and progesterone receptor status
was correlated at q = 0.53, creating problems of multicol-
linearity, analyses only controlled for estrogen receptor status
since it is more closely related to survival than progesterone
receptor status. Furthermore, since treatments for breast
cancer have changed over time and patients of this study were
recruited within a 4-year time frame, we initially included
year of diagnosis as a covariate in the model. However, due to
non-significance, this covariate was ultimately excluded.
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In a first step, proportionality of hazards was examined
by testing the time-dependency of each control or predictor
variable separately. The respective variable was entered
together with its interaction with time in a Cox regression
model. If the variable 9 time interaction turned out to be
significant, this respective variable demonstrates time-
dependent changes in hazards, and a variable 9 time
interaction therefore needs to be included in the multivar-
iate model [27]. Significant time-dependent covariates
were eventually removed if they did not turn out to be
significant in the multivariate model.
Next, a forced entry hierarchical model was chosen
where age was entered in a first step, biomedical (i.e., stage
(if applicable), grade, histology, estrogen receptor, her2
status) entered second, treatment variables (surgery, radi-
ation, chemotherapy, hormonal therapy) entered third,
depression entered fourth, and a depression by age inter-
action entered in the last step.
Age, grade, estrogen receptor status, and her2-neu status
were entered as continuous variables into the Cox regression
equation. Age was mean centered. All other variables (i.e.,
histology, surgery, upfront radiation, initial chemotherapy,
hormonal therapy, depression) were entered as categorical
variables. Depression was categorized at the clinical threshold of
11 and above on the PSSCAN depression subscale. The
depression by age interaction contained depression as a binary
variable and age as a mean centered continuous variable. This
analysis was conducted on the full sample of stage I–III patients,
and was conducted as separate analyses by tumor stage.
To test the significant interaction of depression with age in
patients with stage I breast cancer, the model was rerun with age
centered one standard deviation below the mean (at age 45) and
age centered one standard deviation above the mean (at age 69).
Significant main and interaction effects were visualized by
plotting Kaplan–Meier curves. For this purpose continuous
variables (i.e., age) were categorized one standard deviation
below the mean and less (45 and younger), one standard devi-
ation below to one standard deviation above the mean (from 46
to 68), and one standard deviation above the mean (69 and
older). All statistical tests were two-tailed and a p value of
\0.05 was considered statistically significant. Confidence
intervals are also reported as an alternative indicator of signif-
icance indicating that the population mean will fall within the
respective range in 95 % of samples. Statistical analyses were
conducted with IBM SPSS Statistics Version 21.
Results
Patients
As shown in Table 1, patients’ mean age was 56.19
(SD = 12.54). 1,604 (97.4 %) had non-metastatic breast
cancer (stages I–III) at the time of breast cancer diagnosis
and 42 (2.6 %) were primary metastasized (stage IV). The
largest group of patients (804 (48.8 %)) had stage I breast
cancer. 370 (22.5 %) patients lived on their own. 562
(34.1 %) presented with depressive symptoms, and 260
(15.8 %) of these patients met clinical levels of depression.
As of December 2012, 204 (12.4 %) patients were
deceased, of which 126 (7.7 %) had died of breast cancer.
Median length of survival at the time of data extraction was
74 months. Median follow-up was 76 months.
Prediction of breast cancer-specific and all-cause
mortality (stages I–III)
Joint analysis of patients with curable breast cancer (stages
I–III) demonstrated a main effect of depression on all-
cause mortality but not on breast-cancer specific mortality,
such that depression at the time of cancer diagnosis
increased hazards of all-cause mortality by 50 % compared
to non-depressed patients (HR = 1.54 (95 % CI
1.06–2.25), p = 0.024) while the effect on breast cancer-
specific mortality demonstrated an effect of similar mag-
nitude which, however, only reached marginal significance
(HR = 1.51 (95 % CI 0.95–2.41), p = 0.084) (see Table 2
and Fig. 1). Age did not moderate associations between
depression and breast cancer-specific or all-cause mortality
in patients with breast cancer stages I–III.
Separate analyses by tumor stage
Separate analyses by tumor stage revealed that depression
had an impact on breast cancer-specific mortality and all-
cause mortality in patients with stage I and stage II breast
cancer, but not in patients with stage III or IV breast
cancer. As displayed in Table 3, the hazards of breast
cancer-specific and all-cause mortality is increased by
2–2.5 times in those patients who are depressed compared
to patients who are not depressed1.
Moderator analyses by tumor stage
Moderator analyses testing whether age moderates effects
of depression on mortality only demonstrated a significant
interaction effect of depression and age on all-cause mor-
tality in patients with stage I breast cancer1 (Table 3).
Younger patients at the age of 45 (1 SD below the mean)
with depression had an almost tenfold increase in hazard of
mortality compared to non-depressed patients (HR = 9.82
(95 % CI 2.26–42.68), p = 0.002). Breast cancer patients
1 Due to the fact that in patients with stage I breast cancer only one
depressed patient died of the disease, it was not possible to calculate
breast cancer-specific mortality in this subgroup.
376 Breast Cancer Res Treat (2014) 143:373–384
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with a mean age of 57 had a 3.7-fold increase in hazard of
mortality if they were depressed (HR = 3.69 (95 % CI
1.44–9.48), p = 0.007). Older patients at age 69 (1 SD
above the mean) who were depressed showed a 42 %
increase in hazard of mortality compared to non-depressed
older patients with breast cancer. However, this effect was
not significant (HR = 1.42 (95 % CI 0.48–4.18),
p = 0.530) (Fig. 2).
In neither of the other stages (II–IV) did age moderate
effects of depression on breast cancer-specific or all-cause
mortality (Table 3).
Discussion
The present study prospectively examined the role of
depression at the time of diagnosis in predicting mortality
in patients with breast cancer. In patients with curable
breast cancer (i.e., stages I–III), results demonstrated a










56.13 (12.57) 50.36 (24.14) 56.19 (12.54)
Living situation
Not alone 1,233 (76.9 %) 28 (66.7 %) 1,261 (77.3 %)
Alone 358 (22.3 %) 12 (28.6 %) 370 (22.5 %)
Unknown 13 (0.8 %) 2 (4.8 %) 15 (0.9 %)
Stage
I 804 (50.1 %) 804 (48.8 %)
II 580 (36.2 %) 580 (35.2 %)
III 220 (13.7 %) 220 (13.4 %)
IV 42 (100.0 %) 42 (2.6 %)
Grade
1 366 (22.8 %) 4 (9.5 %) 370 (22.5 %)
2 663 (41.3 %) 15 (35.7 %) 678 (41.2 %)




1,339 (83.5 %) 34 (81.0 %) 1,339 (83.5 %)
Lobular 145 (9.0 %) 4 (9.5 %) 145 (9.0 %)
Other 120 (7.5 %) 4 (9.5 %) 120 (7.5 %)
Estrogen receptor
0 265 (16.5 %) 6 (14.3 %) 267 (16.2 %)
1 57 (3.6 %) 0 (0.0 %) 57 (3.5 %)
2 202 (12.6 %) 5 (11.9 %) 207 (12.6 %)
3 1,079 (67.3 %) 31 (73.8 %) 1,110 (67.4 %)
Unknown 1 (0.1 %) 0 (0.0 %) 5 (0.3 %)
Progesterone receptor
0 403 (25.1 %) 7 (16.7 %) 410 (24.9 %)
1 149 (9.3 %) 5 (11.9 %) 154 (9.4 %)
2 325 (20.3 %) 8 (19.0 %) 333 (20.2 %)
3 505 (31.5 %) 14 (33.3 %) 519 (31.5 %)
Unknown 222 (13.8 %) 8 (19.0 %) 230 (14.0 %)
Her2-neu status
0 1,069 (66.6 %) 26 (61.9 %) 1,095 (66.5 %)
1 170 (10.6 %) 4 (9.5 %) 174 (10.6 %)
2 174 (10.8 %) 7 (16.7 %) 181 (11.0 %)
3 191 (11.9 %) 5 (11.9 %) 196 (11.9 %)
Surgery
Yes 1,594 (99.4 %) 27 (64.3 %) 1,609 (97.8 %)
No 10 (0.6 %) 15 (35.7 %) 37 (2.2 %)
Radiation
Yes 1,212 (75.6 %) 12 (28.6 %) 1,242 (75.5 %)
No 392 (24.4 %) 30 (71.4 %) 404 (24.5 %)
Chemotherapy
Yes 761 (47.4 %) 21 (50.0 %) 782 (47.5 %)






All (n = 1,646)
Hormonal therapy
Yes 1,182 (73.7 %) 9 (21.4 %) 1,215 (73.8 %)
No 422 (26.3 %) 33 (78.6 %) 431 (26.2 %)
Depression
Depressed 250 (15.6 %) 10 (23.8 %) 260 (15.8 %)
Not
depressed
1,354 (84.4 %) 32 (76.2 %) 1,386 (84.2 %)
All-cause mortality
All 176 (11.0 %) 28 (66.7 %) 204 (12.4 %)
Depressed 38 (15.2 %) 7 (70 %) 45 (17.3 %)
Not
depressed
138 (10.2 %) 21 (65.6 %) 159 (11.5 %)
Breast cancer mortality
All 102 (6.4 %) 24 (57.1 %) 126 (7.7 %)
Depressed 26 (10.4 %) 5 (50.0 %) 31 (11.9 %)
Not
depressed











Total person time (months)
All 118,162 2,115 120,277
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Table 2 Cox proportional-hazards regression analyses of patients with curable cancer (n = 1,604)
Breast cancer mortality All-cause mortality
HR (95 % CI) p value HR (95 % CI) p value
1 Age 0.99 (0.98–1.01) 0.404 1.03 (1.02–1.04) \0.001
2 Age 1.00 (0.99–1.02) 0.651 1.04 (1.02–1.05) \0.001
Stage
I 1 1
II 6.32 (3.09–12.92) \0.001 2.93 (1.97–4.37) \0.001
III 12.42 (5.94–25.97) \0.001 5.21 (3.36–8.05) \0.001
Grade 1.92 (1.31-2.82) 0.001 1.53 (1.18–1.99) 0.001
Histology
Invasive ductal 1 1
Lobular 1.15 (0.53–2.49) 0.720 1.10 (0.65–1.86) 0.729
Other 1.19 (0.57–2.47) 0.645 1.12 (0.65–1.95) 0.684
Estrogen receptor 0.83 (0.71–0.98) 0.023 0.90 (0.80–1.03) 0.115
Her2-neu status 0.99 (0.84–1.17) 0.916 1.01 (0.88–1.15) 0.938
3 Age 0.99 (0.98–1.01) 0.532 1.03 (1.01–1.04) \0.001
Stage
I 1
II 8.09 (3.88–16.87) \0.001 3.61 (2.39–5.46) \0.001
III 17.72 (8.09–38.85) \0.001 7.28 (4.50–11.75) \0.001
Grade 2.36 (1.58–3.54) \0.001 1.73 (1.32–2.26) \0.001
Histology
Invasive ductal 1 1
Lobular 1.20 (0.55–2.61) 0.676 1.08 (0.64–1.82) 0.782
Other 0.84 (0.38–1.88) 0.678 0.91 (0.50–1.65) 0.752
Estrogen receptor 0.87 (0.70–1.10) 0.200 0.84 (0.70–1.01) 0.063
Her2-neu status 1.03 (0.87–1.2) 0.751 1.04 (0.91–1.20) 0.532
Surgerya 1 1
0.09 (0.03–0.30) \0.001 0.02 (0.00–0.09) \0.001
Radiationa 1 1
1.88 (1.04–3.33) 0.028 1.10 (0.76–1.58) 0.631
Chemotherapya 1 1
0.35 (0.20–0.60) \0.001 0.44 (0.29–0.67) \0.001
Hormonal therapya 1 1
0.05 (0.01–0.17) \0.001 0.11 (0.04–0.28) \0.001
Surgery 9 time 1.07 (1.01–1.14) 0.025
Hormonal therapy 9 time 1.06 (1.03–1.09) \0.001 1.05 (1.03–1.07) \0.001
4 Age 1.00 (0.98–1.02) 0.667 1.03 (1.01–1.04) \0.001
Stage
I 1 1
II 8.12 (3.90–16.92) \0.001 3.61 (2.39–5.46) \0.001
III 16.90 (7.71–37.06) \0.001 6.94 (4.30–11.21) \0.001
Grade 2.37 (1.58–3.56) \0.001 1.74 (1.33–2.27) \0.001
Histology
Invasive ductal 1 1
Lobular 1.15 (0.53–2.51) 0.719 1.05 (0.62–1.79) 0.846
Other 0.84 (0.37–1.90) 0.676 0.91 (0.50–1.66) 0.761
378 Breast Cancer Res Treat (2014) 143:373–384
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50 % increase in hazard of mortality in depressed versus
non-depressed patients. Analyses by tumor stage revealed
that the effect of depression on mortality is for the most
part driven by patients with earlier stage breast cancer
(stages I and II) where the hazard of mortality for breast
cancer-specific and all-cause mortality was 100–150 %
Table 2 continued
Breast cancer mortality All-cause mortality
HR (95 % CI) p value HR (95 % CI) p value
Estrogen receptor 0.89 (0.71–1.12) 0.321 0.84 (0.70–1.02) 0.073
Her2-neu status 1.02 (0.86–1.20) 0.857 1.03 (0.90–1.18) 0.640
Surgerya 1 1
0.09 (0.03–0.30) \0.001 0.02 (0.00–0.10) \0.001
Radiationa 1 1
1.87 (1.04–3.36) 0.036 1.10 (0.76–1.59) 0.631
Chemotherapya 1 1
0.36 (0.21–0.62) \0.001 0.46 (0.30–0.70) \0.001
Hormonal therapya 1 1
0.05 (0.01–0.17) \0.001 0.11 (0.04–0.28) \0.001
Depression
Not depressed 1 1
Depressed 1.51 (0.95–2.41) 0.084 1.54 (1.06–2.25) 0.024
Surgery 9 time 1.07 (1.01–1.13) 0.033
Hormonal therapy 9 time 1.06 (1.03–1.09) \0.001 1.05 (1.03–1.07) \0.001
5 Age 1.00 (0.98–1.02) 0.971 1.03 (1.02–1.05) \0.001
Stage
I 1 1
II 8.01 (3.84–16.70) \0.001 3.54 (2.34–5.36) \0.001
III 16.79 (7.65–36.84) \0.001 6.85 (4.24–11.06) \0.001
Grade 2.36 (1.58–3.55) \0.001 1.73 (1.32–2.26) \0.001
Histology
Invasive ductal 1 1
Lobular 1.16 (0.53–2.52) 0.713 1.05 (0.62–1.78) 0.851
Other 0.83 (0.37–1.88) 0.658 0.90 (0.49–1.64) 0.730
Estrogen receptor 0.90 (0.71–1.13) 0.349 0.85 (0.71–1.02) 0.084
Her2-neu status 1.01 (0.85–1.19) 0.916 1.03 (0.90–1.18) 0.687
Surgerya 1 1
0.09 (0.03–0.30) \0.001 0.02 (0.00–0.10) \0.001
Radiationa 1 1
1.87 (1.04–3.36) 0.035 1.10 (0.76–1.60) 0.605
Chemotherapya 1 1
0.37 (0.21–0.63) \0.001 0.46 (0.30–0.70) \0.001
Hormonal therapya 1 1
0.05 (0.01–0.16) \0.001 0.11 (0.04–0.28) \0.001
Depression
Not depressed 1 1
Depressed 1.36 (0.80–2.33) 0.259 1.49 (1.00–2.21) 0.049
Surgery 9 time 1.07 (1.01–1.13) 0.034
Hormonal therapy 9 time 1.06 (1.03–1.09) \0.001 1.05 (1.03–1.07) \0.001
Depression 9 age 0.98 (0.94–1.02) 0.360 0.98 (0.94–1.01) 0.155
Test statistics represent hazard ratios with 95 % confidence interval (HR (95 % CI))
a Referent signifies no treatment
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increased in the depressed patients compared to non-
depressed patients with breast cancer. No significant effect
of depression on mortality in patients with breast cancer
stages III and IV was found.
Furthermore, it was shown that age moderated this
effect in patients with stage I breast cancer. In these
patients, an age of 45 (1 SD below the mean) was associ-
ated with an almost tenfold increase in hazard of all-cause
mortality if patients were depressed. This hazard decreased
with age. While the hazard of mortality was still increased
by 270 % in those age 57 years (the mean age of the
sample), a nonsignificant 40 % increase in hazard of
mortality was shown at age 69 (1 SD above the mean) in
depressed older patients with early breast cancer.
As a consequence of advances in treatment for breast
cancer, survival rates have increased over the last two
decades, (as of 2007, 5-year survival rates for curable
breast cancer were 89 % [28]). Consequently, biologic
variables may play less of a role in breast cancer than in
other cancers with less favorable prognoses. The results of
the present study support this assumption, since significant
associations of depression on mortality could be demon-
strated in breast cancer stages I and II, whereas no rela-
tionships could be shown for patients with stages III or IV
breast cancer. In cancers with good prognoses, lifestyle
factors may have a greater influence on outcome than in
cancers with poor prognoses. Given that individuals with
depression often present with an unhealthy lifestyle char-
acterized by poor diet, alcohol abuse, smoking, and lack of
physical activity [29, 30], these factors may play an
important role in determining outcomes in cancer types
with otherwise good prognoses.
However, effects of depression on mortality were largest
in younger women with breast cancer, who on average
have a poorer prognosis than older women with breast
cancer. Due to its side effects, overall adherence rates to
hormonal treatment are only moderate [31]. For younger
premenopausal women, systemic and hormonal treatments
are accompanied by a tremendous decrease in quality of
life compared to postmenopausal women. Therefore,
adherence to hormonal treatment might be lower among
younger women with breast cancer [32] and may depend
on the severity and the perceptions of treatment side
effects. Hormonal treatment is more likely to threaten
young women’s self-concept of being young and fertile,
and as a consequence also has an impact on their self-
esteem [33–35]. Therefore, it is possible that patients high
Depressed 250 244 236 225 218 212
Not Depressed 1354 1344 1311 1259 1227 1216
Fig. 1 Depression as a predictor of overall survival in patients with
curable breast cancer (stages I–III)
Table 3 Cox proportional-hazards regression analyses of depression predicting mortality
Breast cancer mortality All-cause mortality
HR (95 % CI) p value HR (95 % CI) p value
Stage I (n = 804)
Depression n/a n/a 2.30 (1.02–5.15) 0.044
Depression 9 age n/a n/a 0.92 (0.86–0.99) 0.030
Stage II (n = 580)
Depression 2.53 (1.32–4.86) 0.005 2.01 (1.16–3.48) 0.013
Depression 9 age 1.01 (0.95–1.08) 0.735 1.00 (0.95–1.06) 0.918
Stage III (n = 220)
Depression 0.99 (0.47–2.10) 0.979 0.92 (0.47–1.80) 0.801
Depression 9 age 0.99 (0.91–1.07) 0.718 0.95 (0.89–1.02) 0.144
Stage IV (n = 42)
Depression 0.57 (0.16–2.03) 0.388 1.15 (0.38–3.46) 0.807
Depression 9 age 0.95 (0.78–1.16) 0.606 1.06 (0.93–1.21) 0.403
Separate analyses by tumor stage with control of the variables listed in Table 2. Proportionality of hazards was tested within each stage and for
each outcome and adjusted accordingly. Test statistics represent hazard ratios with 95 % confidence interval (HR (95 % CI))
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in depression may demonstrate poorer adherence to hor-
monal treatment as they likely do worse in dealing with its
side effects [36]. Thus, adherence may represent an age
dependent mediator that places younger depressed women
with breast cancer at increased risk of mortality. Given that
data on adherence to hormonal treatment were not avail-
able, we were unable to test this potential mechanism.
Beyond this more behavioral pathway, symptoms of
depression at diagnosis may reveal a woman’s emotional
stress response that coincides with her biologic reactivity to
stressors. This response is likely marked by endocrine and
immunologic changes that may elevate a patient’s biologic
vulnerability to cancer progression [37, 38]. In particular,
inflammation may play an important role in mediating
effects of depression on mortality. Depression is also
known to influence the stress hormone cortisol through
abnormal HPA axis functioning. This process may repre-
sent a second mechanism which might explain poorer
outcome in depressed patients with breast cancer. Again,
younger women with breast cancer who are depressed may
show greater biologic reactivity since they may have more
difficulty coping with cancer and may be more distressed
because of multiple roles and their demands (e.g., raising
under-aged children, having a larger household, managing
work or a career) which tend to decrease with age.
The predictive relationship of depression could be more
consistently demonstrated for all-cause compared to breast
cancer-specific mortality. It is well-known that the reli-
ability of the documentation of breast cancer-specific sur-
vival is not as high as for overall survival, and is therefore
less valid. However, there were few discrepancies in
findings between all-cause and breast cancer-specific
mortality; the missing significance of depression as a pre-
dictor of breast cancer-specific mortality approached sig-
nificance and the hazard ratio was the same size as the
hazard ratio for all-cause mortality. The majority of pre-
vious studies did not differentiate between breast cancer-
specific and overall survival.
This study should be interpreted in the context of its
strengths and limitations. The relatively brief depression
measure does not substitute for a diagnosis of depression
based on a structured clinical interview. However, this
study was population-based in nature and thus a time-
intensive and costly assessment of mental disorders via
structured interviews was not feasible, thus necessitating
the use of an established cancer-specific screening tool.
Although the use of a structured clinical interview would
have theoretically been superior, it most likely would have
resulted in a significant increase in patients declining par-
ticipation in a study with a much longer time commitment
(which a structured clinical interview would have required)
Depressed 69 67 65 61 58 55
Not Depressed 279 277 271 263 256 254
Depressed 159 157 151 144 141 139
Not Depressed 808 803 791 768 758 751
Depressed 22 20 20 20 19 18
Not Depressed 267 263 249 228 213 211
Fig. 2 Age moderating the relationship between depression and
overall survival in stage I breast cancer. Age B45 years are patients at
least 1 SD below the mean, age 46–68 years are patients within 1 SD
above or below the mean, and age C69 years are patients 1 SD above
the mean
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at the time of cancer diagnosis. Furthermore, this likely
would result in a selection bias, where younger, fitter
patients would be more likely to participate [39].
Conversely, some misclassifications may have occurred
with the approach chosen. Responders and non-responders to
the screening questionnaire did not differ in any clinical
variables except for an average age difference of 2.6 years,
and therefore, the slightly younger patient sample may have
been more distressed than breast cancer patients in British
Columbia on average. However, prevalence rates of depres-
sion in the current study match well with results from other
larger scale studies on women with breast cancer [40, 41].
Further, the epidemiological nature of this study pre-
vented us from collecting data on depression over time in
order to consider various trajectories of depression and how
these may be related to mortality. This is an important area
for future research to examine. Further, although the
sample was well described in terms of tumor stage, grade,
hormone receptor status, and treatments received, no data
had been collected for performance status, reproductive
information, or comorbidities. Performance status in par-
ticular is a strong predictor of survival, but is correlated
with mental health. As well, only few demographic vari-
ables had been documented.
The assessment of depression at a fixed time point,
namely post-cancer diagnosis, reduces error variance.
Consequently, assessments were not confounded with
emotional reactions arising from cancer treatment and its
side effects. However, because the depression measure was
collected before patients were given their prognosis and
treatment plan, there may have been reduced variance in
depression scores. This may have served to make the results
of this study conservative. As well, patients were recruited
within a routine program for emotional distress screening.
Hence, the sample can be considered representative of the
Greater Vancouver region and of sufficient size such that
analyses do not suffer a lack of statistical power.
Directions for future research
Whether effective treatment of depression improves sur-
vival in patients with breast cancer remains to be deter-
mined. Some evidence suggests that a decrease in depression
in patients with metastatic breast cancer is associated with
lower mortality [42]. Following the observational findings
of this study, it would be interesting to explore whether there
are benefits to survival when patients high in depression
make use of the various sources of counseling or psycho-
therapy that have been established for women with breast
cancer in the last few years. As well, exploring the two
mechanisms (i.e. positive behavior change in life style and
adherence, decrease in inflammation) proposed, explaining
differences in survival among depressed as opposed to not
depressed patients with breast cancer in intervention studies,
would result in a better understanding of the associations
identified in the present study.
Clinical implications
The great impact of depression on mortality, especially in
younger women with early stage breast cancer, exemplifies
the importance of routine screening programs for depres-
sion in the cancer care context. Along with systematic
screening, there must be a consistent referral procedure in
place so that depressed patients receive psychological
treatment in a timely manner. A broad spectrum of tech-
niques can support patients in overcoming their depression
and coping with a cancer diagnosis. Cognitive-behavioral
therapy has been shown to be the most efficacious method
of treatment for depression, and not only treats symptoms of
depression but can also influence behavioral factors that are
related to cancer treatment and survivorship [43, 44].
Whether antidepressant treatment alone can replace cogni-
tive-behavioral therapy in terms of its effects in reducing
depressive symptoms and behaviors remains to be deter-
mined. It is likely that antidepressants represent a support-
ive treatment but might not be able to promote favorable
behavior change.
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